FACTORS ASSOCIATED WITH PREVENTABLE SEVERE EXTRAPYRAMIDAL SYMPTOMS FROM ANTIPSYCHOTIC USE IDENTIFIED USING BENZTROPINE AS A TRIGGER TOOL
DOI:
https://doi.org/10.69598/tbps.21.1.71-85Keywords:
preventable adverse drug events, antipsychoticsAbstract
Preventable adverse drug events (ADEs) are critical targets for detection to ensure patient safety. This study aimed to evaluate factors associated with the occurrence of preventable ADEs among patients receiving benztropine, used as a trigger tool for monitoring severe extrapyramidal symptoms in patients treated with antipsychotics. A retrospective study was conducted by reviewing patient medical records at Saraburi Hospital. The population comprised all patients who received benztropine at Saraburi Hospital between October 1, 2021, and September 30, 2024. The sample included those who met the inclusion criteria of receiving antipsychotics and assessing ADEs, excluding cases with incomplete, abnormal, or implausible data. Collected data included patient demographic characteristics and clinical data. Data were analyzed using descriptive statistics, and the associations between variables were examined using the chi-square test or fisher’s exact test, as appropriate. Subsequently, univariate binary logistic regression was performed to assess the factors affected with the occurrence of preventable and non-preventable ADEs. The univariate analysis of 62 patients, of whom 38 experienced preventable ADEs, most factors were not significantly associated with the occurrence of preventable ADEs. However, the duration of antipsychotic use showed a statistically significant association with the occurrence of preventable ADEs (p-value = 0.017). Patients who had received antipsychotic treatment for more than 4 months were approximately 5.83 times more likely to experience preventable ADEs compared with those who had received treatment for 4 months or less (OR = 5.833). The findings indicated that prolonged use of antipsychotics for more than 4 months was associated with preventable ADEs. Therefore, regular monitoring and risk assessment should be implemented, along with the development of pharmacovigilance systems, to prevent such events in this patient group.
References
Rattanadetsakul P, Rattanadetsakul C. Reducing the risk of medication use through adverse drug reaction (ADR) data. [Internet]. 2017 [cited 2024 Oct 27]. Available from: https://ccpe.pharmacycouncil.org/index.php?option=article_detail&subpage=article_detail&id=312 (in Thai)
Tragulpiankit P. Trigger tools for enhancing the detection and prevention of medication-related harm. In: Jindawijak B, Suansanae T, Chulavatnatol S, Montakantikul P, editors. Advances in pharmaceutics and pharmacy practice. Bangkok: Prachachon; 2011. p.184–96. (in Thai)
Urairerkul C. Medication management system (MMS) [Internet]. 2019 [cited 2024 Oct 27]. Available from: https://hpc.go.th/standard/ha2018/topicDisplay.php?id=10 (in Thai)
Resar R, Rozich JD, Classen D. Methodology and rationale for the measurement of harm with trigger tools. Qual Saf Health Care. 2003;12(Suppl 2):ii39-45.
Rozich J, Haraden C, Resar R. Adverse drug event trigger tool: A practical methodology for measuring medication related harm. Qual Saf Health Care. 2003;12(3):194-200.
Yothapitak J, Songsiripong R. The use of trigger tools in detecting adverse drug events. In: Suansanae T, Jindawijak B, editors. Milestones to professionalism: Hospital pharmacists. Bangkok: The Association of Hospital Pharmacy (Thailand); 2009. p.140-54. (in Thai)
Suksanan P. Case study: The use of kayexalate as an indicator of hyperkalemia in hospitalized patients (abstract presented at a conference). In: Suansanae T, Jindawijak B, editors. Milestones to professionalism: Hospital pharmacists. Bangkok: The Association of Hospital Pharmacy (Thailand); 2009. p.239. (in Thai)
Yeesoonpan N, Tragulpiankit P, Kaeratigachakorn W, Uaviseswong T, Ninsananda T, Chaikledkaew U, et al. Detecting adverse drug events by trigger tool at a provincial hospital in Thailand. Thai J Pharm Pract. 2015;7(2):234-49. (in Thai)
Theraratchilert P, Chanakul W, Mongkolnavin J, Sathienluckana T, Suwattanapreeda S, Tiangphattanawong P, et al. Development of a predictive model for serious adverse drug reaction in psychiatric patients leading to the use of benztropine injection by using data mining techniques. Thai J Pharm Pract. 2023;15(2):523-35. (in Thai)
Wananukul W. Adverse reactions of psychotropic drugs and management [Internet]. 2014 [cited 2024 Oct 15]. Available from: https://www.rama.mahidol.ac.th/poisoncenter/sites/default/files/public/pdf/books/Antidote_book4-06_Adverse-Reactions-of-Psychotropic-Drugs-and-Management.pdf (in Thai)
Weng J, Zhang Y, Li H, Shen Y, Yu W. Study on risk factors of extrapyramidal symptoms induced by antipsychotics and its correlation with symptoms of schizophrenia. Gen Psychiatr. 2019;32(1):1-8.
Kroken RA, Johnsen E, Ruud T, Wentzel-Larsen T, Jørgensen HA. Treatment of schizophrenia with antipsychotics in Norwegian emergency wards, a cross-sectional national study. BMC Psychiatry. 2009;9:24:1-9
Griffin FA, Resar RK. IHI global trigger tool for measuring adverse events. 2nd ed. Cambridge (MA): Institute for Healthcare Improvement; 2009.
National Coordinating Council for Medication Error Reporting and Prevention. Contemporary view of medication-related harm. A new paradigm [Internet]. 2015 [cited 2024 Oct 15]. Available from: https://www.nccmerp.org/sites/default/files/nccmerp_fact_sheet_2015-02-v91.pdf
Haddad PM, Brain C, Scott J. Nonadherence with antipsychotic medication in schizophrenia: Challenges and management strategies. Patient Relat Outcome Meas. 2014;23(5):43-62.
StataCorp. Stata statistical software: Release 18. College Station (TX): StataCorp LLC; 2023.
Pérez Zapata AI, Gutiérrez Samaniego M, Rodríguez Cuéllar E. Ruiz López P. Detection of adverse events in general surgery by applying the "Trigger Tool" methodology. Cir Esp. 2015;93(2):84–90.
Assiri GA, Bin Shihah AS, Alkhalifah MK, Alshehri AS, Alkhenizan AH. Identification and characterization of preventable adverse drug events in family medicine clinics from central Saudi Arabia. Saudi J Med Med Sci. 2023;11(1):26-35.
Bates DW, Cullen DJ, Laird N, Petersen LA, Small SD, Servi D, et al. Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group. JAMA. 1995;274:29–34.
Abu-Naser D, Gharaibeh S, Al Meslamani AZ, Alefan Q, Abunaser R. Assessment of extrapyramidal symptoms associated with psychotropics pharmacological treatments, and associated risk factors. Clin Pract Epidemiol Ment Health. 2021;17:1-7.
Huang Y, Pan L, Teng F, Wang G, Li C, Jin L. A Cross-sectional study on the characteristics of tardive dyskinesia in patients with chronic schizophrenia. Shanghai Arch Psychiatry. 2017;29(5):295-303.
Downloads
Published
How to Cite
Issue
Section
License
All articles published and information contained in this journal such as text, graphics, logos and images is copyrighted by and proprietary to the Thai Bulletin of Pharmaceutical Sciences, and may not be reproduced in whole or in part by persons, organizations, or corporations other than the Thai Bulletin of Pharmaceutical Sciences and the authors without prior written permission.
